JPM23: Is Novartis weighing respiratory, eye drug sell-offs after Sandoz? Not necessarily, CEO says

Novartis has been narrowing its focus to innovative medicines, and, more specifically, five therapeutic areas. But that doesn’t mean the Swiss pharma will leave respiratory and eye diseases altogether, CEO Vas Narasimhan said Monday.